Figure 1.

Characteristics of the patients who received greater than 30 mg IM per month of LAR. Number of patients with improvement in symptoms, tumor markers, and tumor burden. The vertical axis denotes the number of patients. The light green portion of the column indicates the proportion of patients with no improvement in symptoms/5-HIAA/CGA, while the dark blue portion denotes improvement. For “tumor size” the light green denotes tumor progression, while the dark blue denotes stable disease. IM, intramuscular; LAR, long-acting release; 5-HIAA, 5-hydoxyindoacetate; CGA, chromogranin A.